These exploratory subpopulation findings are hypothesis-generating and do not change the regulatory path for fasedienol. Monitor for any announced Phase 3 design changes or regulatory interactions that could follow from these data.
Price Chart
Executive Summary
Vistagen reported positive exploratory data for fasedienol nasal spray in very severe social anxiety disorder at Psych Congress 2026. Subpopulation analyses from two prior trials (PALISADE-4 Phase 3 and a Phase 2a repeat-dose study) showed statistically significant improvements on the SUDS scale in patients with baseline LSAS ≥95, though the Phase 3 study did not meet its primary endpoint in the total population. The data are exploratory and post-hoc; no regulatory or financial catalysts are announced.
Key Facts
- Exploratory data presented at Psych Congress 2026 for fasedienol in very severe SAD (LSAS ≥95)
- Post-hoc analysis of PALISADE-4 Phase 3 showed statistically significant SUDS benefit in the very severe subpopulation, though the study missed its primary endpoint overall
- Prespecified analysis of a Phase 2a repeat-dose study showed statistically significant improvement after a single dose and greater numerical improvement after a second dose
- No serious drug-related safety signals identified; safety consistent with prior trials
- No financial figures, guidance changes, or regulatory milestones provided in the filing
Financial Impact
No financial impact disclosed; exploratory data only
Risk Factors
- PALISADE-4 failed its primary endpoint in the total population; the positive subpopulation signal is post-hoc and may not replicate
- No timeline or commitment to a new Phase 3 trial has been provided
- Fasedienol remains unapproved; regulatory and commercial risks are unchanged
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-063316 |
| Exhibit: ex99120260924.htm | 0001628280-26-063316 |
| Document: 0001628280-26-063316-index-headers.html | 0001628280-26-063316 |
| Document: 0001628280-26-063316-index.html | 0001628280-26-063316 |
| Document: 0001628280-26-063316.txt | 0001628280-26-063316 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $0.2300 $0.2000 | ▼ −13.04% | ▼ −11.55% | $0.1700 (−26.09%) |
Sep 25, 2026 4w ago | 8-K | $0.2700 $0.2800 | ▲ +3.70% | ▲ +3.93% | $0.1700 (−37.04%) |
Sep 24, 2026 4w ago | 8-K | $0.2950 $0.2826 | ▼ −4.20% | ▼ −3.79% | $0.1700 (−42.37%) |
Sep 24, 2026 4w ago | Press Release | $0.2950 $0.2826 | ▼ −4.20% | ▼ −3.79% | $0.1700 (−42.37%) |
Aug 14, 2026 10w ago | 8-K | $0.2676 $0.2440 | ▲ +8.82% | ▲ +7.45% | $0.1700 (+36.47%) |
Aug 14, 2026 10w ago | Press Release | $0.2676 $0.2440 | ▼ −8.82% | ▼ −7.45% | $0.1700 (−36.47%) |
Jul 31, 2026 12w ago | 8-K | $0.2410 $0.2876 | ▲ +19.34% | ▲ +15.82% | $0.1700 (−29.46%) |
Jun 30, 2026 17w ago | 8-K | $0.2260 $0.2458 | ▼ −8.76% | ▼ −8.16% | $0.1700 (+24.78%) |
Jun 17, 2026 18w ago | 8-K | $0.6702 $0.6166 | ▼ −8.00% | ▼ −6.33% | $0.1700 (−74.63%) |
Jun 15, 2026 19w ago | 8-K | $0.6900 $0.6323 | ▼ −8.36% | ▼ −6.13% | $0.1700 (−75.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers